Iovance Biotherapeutics (IOVA)
Commercializes TIL cell therapies for melanoma and other solid-tumor settings.
Something off on this page? Send us feedback.
Sells Amtagvi and Proleukin, pairing an FDA-approved TIL cell therapy with the interleukin-2 product used in treatment and manufacturing. Operations center on oncology access, cell-therapy manufacturing, authorized treatment centers, and confirmatory evidence required under accelerated approval.
Markets Amtagvi, a lifileucel TIL cell therapy for previously treated unresectable or metastatic melanoma, alongside Proleukin, the aldesleukin product used in the Amtagvi regimen and sold for other oncology, manufacturing, clinical, and research uses.
Commercial work is centered in U.S. oncology channels, with Canadian conditional authorization extending the same core melanoma therapy into another regulated market. Manufacturing is built around the Iovance Cell Therapy Center in Philadelphia, nearby contract capacity, and authorized treatment centers that collect and ship tumor tissue.
Execution depends on patient access, reliable cell-therapy manufacturing, Proleukin supply and use, and confirmatory evidence required by the accelerated-approval pathway. Promotional materials also operate under FDA scrutiny after the agency challenged exploratory overall-survival claims.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Barclays | Reiterate | Rating: —Target: $13 | Target: $15 |
| Aug 20, 2026 | UBS | Reiterate | Rating: —Target: $2 | Target: $7 |
| Aug 18, 2026 | Mizuho Securities | Target | Target: — | Target: $11 |
| Aug 7, 2026 | Robert W. Baird | Target | Target: $24 | Target: $6 |
| Aug 7, 2026 | Barclays | Reiterate | Rating: —Target: $40 | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $297.7M · Total debt $46.0M · Total assets $915.5M · Shareholders' equity $736.0M
- Revenue
- $99.3M
- Operating income
- −$51.9M
- Net income
- −$47.3M
No dividends on record.
| Institutions | ≈ 63.31% | 286.79M shares | |
|---|---|---|---|
| 305 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.33% | 1.47M shares | |
| 9 holders · as of Sep 10, 2026 | |||
| Other | ≈ 36.36% | 164.70M shares | |
| remainder | |||
452.97M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.16% | 36.96M | as of Jun 30, 2026 |
MHR Fund Management LLCInstitution | 6.39% | 28.97M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.40% | 24.48M | as of Jun 30, 2026 |
Two Sigma Investments, LPInstitution | 4.20% | 19.01M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.02% | 18.20M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Merck
PD-1 backbone in melanoma and solid-tumor immunotherapy
- Bristol-Myers Squibb
Checkpoint and LAG-3 melanoma incumbent with Opdivo, Yervoy, Opdualag
- Novartis (ADR)
BRAF/MEK targeted melanoma competitor via Tafinlar and Mekinist
- Pfizer
BRAF/MEK melanoma challenger through Braftovi and Mektovi
- Replimune Group
Oncolytic immunotherapy challenger in anti-PD-1-failed melanoma
- Immatics
PRAME TCR-T program targeting post-checkpoint advanced melanoma
- Immunocore (ADR)
TCR bispecific incumbent in metastatic uveal melanoma
- Amgen
Approved oncolytic-virus niche in injectable melanoma lesions
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics | $10.23 | −3.85% | $4.75B | — | — | 14.6 | +65.7% |
| Merck | $147.28 | −2.41% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $61.73 | −0.84% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Novartis (ADR) | $142.23 | +0.67% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Pfizer | $28.01 | +0.27% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Replimune Group | $12.74 | −5.42% | $1.13B | — | — | — | — |
| Immatics | $8.64 | −2.63% | $1.19B | — | — | 25.0 | +113.0% |
| Immunocore (ADR) | $31.13 | −3.99% | $1.65B | — | — | 4.1 | −13.7% |
| Amgen | $404.97 | −1.28% | $221.41B | 25.5 | 17.3 | 5.8 | +9.7% |
| Median | 25.5 | 15.1 | 4.8 | +5.1% |